These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 1385198)

  • 21. Effects of recombinant human granulocyte colony-stimulating factor on the mice receiving bone marrow transplantation following lethal irradiation: acceleration of recovery of the peripheral blood neutrophils and potentiation of anti-Pseudomonas resistance.
    Tamura M; Matsumoto M; Yoshino T; Matsubara S; Imai N; Ono M; Yokota T
    Exp Hematol; 1991 Jan; 19(1):18-23. PubMed ID: 1703491
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect of recombinant human granulocyte colony stimulating factor (rhG-CSF) in patients receiving chemotherapy--phase I study].
    Fukutani H; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Nagamine D; Shinagawa K; Tabata M; Hirano A; Mizunuma N
    Gan To Kagaku Ryoho; 1989 May; 16(5):2005-12. PubMed ID: 2471461
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abnormal bactericidal, metabolic, and lysosomal functions of Chediak-Higashi Syndrome leukocytes.
    Root RK; Rosenthal AS; Balestra DJ
    J Clin Invest; 1972 Mar; 51(3):649-65. PubMed ID: 4400956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect of recombinant human granulocyte colony-stimulating factor on white blood cell count and neutrophil functions in patients with malignant lymphoma].
    Ashida T; Ishikawa H; Urase F; Satoh M; Tsubaki K; Horiuchi A
    Rinsho Ketsueki; 1989 Oct; 30(10):1778-82. PubMed ID: 2480462
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study of intravenously administered bacterially synthesized granulocyte-macrophage colony-stimulating factor and comparison with subcutaneous administration.
    Lieschke GJ; Maher D; O'Connor M; Green M; Sheridan W; Rallings M; Bonnem E; Burgess AW; McGrath K; Fox RM
    Cancer Res; 1990 Feb; 50(3):606-14. PubMed ID: 2404573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Defective granulocyte chemotaxis in the Chediak-Higashi syndrome.
    Clark RA; Kimball HR
    J Clin Invest; 1971 Dec; 50(12):2645-52. PubMed ID: 4942966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Restoration of neutrophil and platelet function in feline Chediak-Higashi syndrome by bone marrow transplantation.
    Colgan SP; Hull-Thrall MA; Gasper PW; Gould DH; Rose BJ; Fulton R; Blanquaert AM; Bruyninckx WJ
    Bone Marrow Transplant; 1991 May; 7(5):365-74. PubMed ID: 2070146
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Experimental study on safety for granulopoiesis in simultaneous therapy with recombinant human granulocyte colony-stimulating factor and chemotherapy.
    Kabaya K; Obuchi M; Watanabe M; Kusaka M; Seki M
    Oncol Res; 1995; 7(3-4):165-71. PubMed ID: 8555650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Administration of human recombinant granulocyte colony-stimulating factor (filgrastim) accelerates granulocyte recovery following high-dose chemotherapy and autologous marrow transplantation with 4-hydroperoxycyclophosphamide-purged marrow in women with metastatic breast cancer.
    Kennedy MJ; Davis J; Passos-Coelho J; Noga SJ; Huelskamp AM; Ohly K; Davidson NE
    Cancer Res; 1993 Nov; 53(22):5424-8. PubMed ID: 7693341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Haematological, bone marrow and clinical chemical changes in neonatal foals given canine recombinant granulocyte-colony stimulating factor.
    Zinkl JG; Madigan JE; Fridmann DM; Kabbur MB; Reynal-O'Connor J; Andresen JW
    Equine Vet J; 1994 Jul; 26(4):313-8. PubMed ID: 8575399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of recombinant granulocyte colony-stimulating factor treatment on hematopoietic cycles and cellular defects associated with canine cyclic hematopoiesis.
    Pratt HL; Carroll RC; McClendon S; Smathers EC; Souza LM; Lothrop CD
    Exp Hematol; 1990 Dec; 18(11):1199-203. PubMed ID: 1699776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hematological effect of 14 days treatment of recombinant human granulocyte colony-stimulating factor for neutropenia in myelodysplastic syndromes].
    Yoshida Y; Hirashima K; Asano S; Takaku F; Furusawa S; Ogawa T; Arimori S; Abe T; Suzuki T; Kato Y
    Rinsho Ketsueki; 1991 Jul; 32(7):743-50. PubMed ID: 1717726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and adverse events following 5-day repeated administration of lenograstim, a recombinant human granulocyte colony-stimulating factor, in healthy subjects.
    Akizuki S; Mizorogi F; Inoue T; Sudo K; Ohnishi A
    Bone Marrow Transplant; 2000 Nov; 26(9):939-46. PubMed ID: 11100272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and pharmacodynamics of recombinant human granulocyte-colony stimulating factor after intravenous and subcutaneous administration in the rat.
    Tanaka H; Okada Y; Kawagishi M; Tokiwa T
    J Pharmacol Exp Ther; 1989 Dec; 251(3):1199-203. PubMed ID: 2481032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Chédiak-Higashi syndrome. Evidence that defective leukotaxis is primarily due to an impediment by giant granules.
    Clawson CC; White JG; Repine JE
    Am J Pathol; 1978 Sep; 92(3):745-53. PubMed ID: 686156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of prolonged treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor.
    Greenberg P; Negrin R; Nagler A; Vincent M; Donlon T
    Int J Cell Cloning; 1990 Jan; 8 Suppl 1():293-300; discussion 300-2. PubMed ID: 1691248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Growth factors G-CSF and GM-CSF differentially preserve chemotaxis of neutrophils aging in vitro.
    Wolach B; van der Laan LJ; Maianski NA; Tool AT; van Bruggen R; Roos D; Kuijpers TW
    Exp Hematol; 2007 Apr; 35(4):541-50. PubMed ID: 17379064
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of recombinant canine granulocyte-colony stimulating factor to increase leukocyte count in dogs naturally infected by canine parvovirus.
    Armenise A; Trerotoli P; Cirone F; De Nitto A; De Sario C; Bertazzolo W; Pratelli A; Decaro N
    Vet Microbiol; 2019 Apr; 231():177-182. PubMed ID: 30955806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of granulocyte colony-stimulating factor treatment on ex vivo neutrophil functions in nonneutropenic surgical intensive care patients.
    Gerber A; Struy H; Weiss G; Lippert H; Ansorge S; Schulz HU
    J Interferon Cytokine Res; 2000 Dec; 20(12):1083-90. PubMed ID: 11152575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of recombinant canine granulocyte colony-stimulating factor to decrease myelosuppression associated with the administration of mitoxantrone in the dog.
    Ogilvie GK; Obradovich JE; Cooper MF; Walters LM; Salman MD; Boone TC
    J Vet Intern Med; 1992; 6(1):44-7. PubMed ID: 1372355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.